Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Directorate Change

30 Aug 2011 07:00

RNS Number : 1482N
Immunodiagnostic Systems Hldgs PLC
30 August 2011
 



 

Immunodiagnostic Systems Holdings plc

("IDS" or the "Company")

 

Directorate Change

 

Immunodiagnostic Systems Holdings plc (AIM: IDH), a leading producer of specialist diagnostic testing kits for the clinical and research markets, announces that Anthony "Tony" Wilks, Sales and Marketing Director, will step down from his board position on 1 September. Tony, who now resides in Germany, will continue to work for the Group in a new role. The Company also announces that from the same date Lynda A. Merrill has been appointed as Group Sales and Marketing Director.

 

Lynda joins IDS most recently from QIAGEN N.V. ("QIAGEN"), where she was Vice President, Molecular Diagnostics Sales for the EMEAA (Europe, Middle East, Africa and Asia) region, responsible for the total diagnostics business for QIAGEN. Prior to this, Lynda spent 10 years working for Gen-Probe, a San Diego based company that develops, manufactures and markets rapid Nucleic Acid Tests. Lynda held a number of roles at Gen-Probe including Vice President for Industrial Relationships and Vice President of World Wide Marketing and Sales. In the latter of the two roles, she implemented global marketing and pricing strategies and grew product revenues from $96m in 1999 to $223m in 2003.

 

Ian Cookson, Chief Executive of Immunodiagnostic Systems Holdings plc, commented: "The Board would like to thank Tony for his contribution to the development of IDS since joining us in 2004 and I am pleased he is remaining within the Group. At the same time, we are very excited about welcoming Lynda to IDS and look forward to developing the sales and marketing team further by being able to draw on her wealth of experience on both sides of the Atlantic."

 

For further information:

 

Immunodiagnostic Systems Holdings plc

Tel: 0191 519 0660

Ian Cookson, Chief Executive Officer

Paul Hailes, Finance Director

 

 

 

Brewin Dolphin

Tel: 0845 213 4930

Matt Davis

Sean Wyndham-Quin

Luke Boyce

 

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

paul.mcmanus@walbrookpr.com

Fiona Henson

fiona.henson@walbrookpr.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGUBURUPGGAQ
Date   Source Headline
17th May 20217:00 amRNSOffer for Immunodiagnostic Systems Holdings Plc
16th Apr 20217:00 amRNSFY21 Trading Update
29th Mar 20217:00 amRNSFDA EUA for automated IgG SARS-CoV-2 assay
27th Nov 20209:05 amRNSSecond Price Monitoring Extn
27th Nov 20209:00 amRNSPrice Monitoring Extension
27th Nov 20207:00 amRNSLaunch of SARS-CoV-2 Antigen Rapid Tests
20th Nov 20206:22 pmRNSInterim Results - period ended 30 September 2020
26th Oct 20209:05 amRNSSecond Price Monitoring Extn
26th Oct 20209:00 amRNSPrice Monitoring Extension
23rd Oct 20204:35 pmRNSH1 Trading Update
9th Oct 20207:00 amRNSAssay to detect IgM SARS-CoV-2 antibodies launch
16th Sep 20207:00 amRNSNew TDM assays launched for use on the IDS-iSYS
14th Sep 20202:39 pmRNSDirector/PDMR Shareholding
27th Aug 20207:00 amRNSSARS-CoV-2 manufacturing agreement
13th Aug 20204:40 pmRNSSecond Price Monitoring Extn
13th Aug 20204:35 pmRNSPrice Monitoring Extension
13th Aug 20207:00 amRNSAutomated IgM assay to detect SARS-CoV-2
4th Aug 20204:18 pmRNSLaunch of automated IDS Cortisol assay
23rd Jul 20202:57 pmRNSResults of AGM
23rd Jul 20207:00 amRNSAGM Statement
17th Jul 202010:40 amRNSDirector/PDMR Shareholding
16th Jul 20201:45 pmRNSDirector/PDMR Shareholding
30th Jun 20209:05 amRNSSecond Price Monitoring Extn
30th Jun 20209:00 amRNSPrice Monitoring Extension
30th Jun 20207:00 amRNSLaunch of assay to detect SARS-CoV-2 antibodies
17th Jun 20208:35 amRNSPublication of Annual Report and Accounts
17th Jun 20207:00 amRNSFinal Results
12th Jun 20209:06 amRNSSecond Price Monitoring Extn
12th Jun 20209:00 amRNSPrice Monitoring Extension
12th Jun 20207:00 amRNSAutomated assay to detect SARS-CoV-2 antibodies
17th Apr 20204:35 pmRNSFY20 Trading Update
31st Mar 202011:00 amRNSDirector/PDMR Shareholding
21st Feb 20204:11 pmRNSDirector/PDMR Shareholding
21st Feb 20209:11 amRNSDirector/PDMR Shareholding
20th Feb 20204:49 pmRNSDirector/PDMR Shareholding
22nd Nov 20194:35 pmRNSHalf-year Report
18th Oct 20194:35 pmRNSTrading Statement
25th Jul 20193:34 pmRNSResult of AGM
25th Jul 20197:00 amRNSAGM Statement
11th Jul 20192:16 pmRNSDirector/PDMR Shareholding
5th Jul 201910:02 amRNSDirector/PDMR Shareholding
19th Jun 20197:05 amRNSPublication of Annual Report and Accounts
19th Jun 20197:00 amRNSFinal Results
22nd May 20192:05 pmRNSSecond Price Monitoring Extn
22nd May 20192:00 pmRNSPrice Monitoring Extension
18th Apr 20194:35 pmRNSFY2019 Trading Update
12th Mar 201911:55 amRNSChange of Auditor
7th Jan 20198:20 amRNSDirector/PDMR Shareholding
18th Dec 20181:42 pmRNSDirector/PDMR Shareholding
6th Dec 20185:13 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.